In February this year, the "Action Plan for Building a High-standard Market System" clearly proposed to formulate anti-monopoly guidelines and exemption system application guidelines for special fields such as APIs; In 2020, the Anti-monopoly Committee of the State Council also promulgated the Anti-monopoly Guide in the Field of APIs (Draft for Comment) through the State Administration of Markets.
Liu Xu said that the above draft for comments has not been officially released, and its progress is still unclear. It is expected that it may be released this year.
There is a precedent of anti-monopoly in the field of APIs. The aforementioned Xiansheng Technology and Tianyao Holdings were both punished for the monopolistic behavior of APIs.
Zhao Heng, founder of Latitude Health, a pharmaceutical strategy consulting company, believes that the number of raw material drug enterprises in China is relatively small, and the anti-monopoly punishment may be one-off. "If companies fail to comply, they will be greatly affected." However, many enterprises are taking advantage of this monopoly in the sales process, which will have a great deterrent effect.
Shi Lichen believes that the punishment of Yang Zijiang Pharmaceutical shows that the anti-monopoly of the pharmaceutical industry has entered the field of preparations from the field of raw materials, and the compliance requirements for pharmaceutical companies have been greatly improved, which has also prompted the operation of pharmaceutical companies to be more standardized.
Liu Xu told the newspaper that anti-monopoly cases in the pharmaceutical industry used to focus on chemicals. It can be seen from the ticket issued by Yang Zijiang Pharmaceutical that it is a good supplement to start paying attention to the anti-monopoly in the field of Chinese patent medicines.